Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Jessica Newcomb Sells 7,031 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Jessica Newcomb sold 7,031 shares of Tango Therapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $22.42, for a total value of $157,635.02. Following the completion of the transaction, the insider owned 52,090 shares of the company’s stock, valued at approximately $1,167,857.80. This represents a 11.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jessica Newcomb also recently made the following trade(s):

• On Tuesday, September 22nd, Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00.

Tango Therapeutics Stock Performance

TNGX opened at $20.87 on Friday. The stock’s 50 day moving average price is $23.41 and its 200-day moving average price is $22.43. Tango Therapeutics, Inc. has a one year low of $7.37 and a one year high of $34.39. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -24.55 and a beta of 1.26.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, analysts predict that Tango Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNGX. Nykredit A S acquired a new position in Tango Therapeutics in the second quarter valued at about $26,000. Allworth Financial LP acquired a new position in shares of Tango Therapeutics in the second quarter worth $35,000. Sterling Capital Management LLC increased its holdings in Tango Therapeutics by 838.8% during the 3rd quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock worth $116,000 after purchasing an additional 4,152 shares during the period. Global Retirement Partners LLC acquired a new stake in Tango Therapeutics in the second quarter valued at approximately $122,000. Finally, State of Wyoming acquired a new stake in shares of Tango Therapeutics in the 1st quarter valued at $128,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TNGX shares. Guggenheim increased their price objective on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a research note on Friday, October 23rd. JPMorgan Chase & Co. started coverage on shares of Tango Therapeutics in a report on Wednesday, July 15th. They issued an “overweight” rating and a $46.00 price target on the stock. Wall Street Zen lowered shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Mizuho upped their target price on Tango Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tango Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $44.62.

About Tango Therapeutics

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.